乐伐替尼治疗非病毒性不可切除肝细胞癌的疗效

StephenW

乐伐替尼治疗非病毒性不可切除肝细胞癌的疗效
Tetsu Tomonari 1，Yasushi Sato 2，Hironori Tanaka 1，Takeshi Mitsuhashi 1，Akihiro Hirao 1，Takahiro Tanaka 1，Tatsuya Taniguchi 1，Koichi Okamoto 1，Masahiro Sogabe 1，Hiroshi Miyayama 1，Takeshi Mitsuhashi 1，Takahiro Tanaka 1
隶属关系
隶属关系

    1
    胃肠病学和肿瘤学系，生物医学科学研究所德岛大学研究生院日本德岛。
    2
    胃肠病学和肿瘤学社区医学系德岛大学生物医学科学研究生院日本德岛。

    PMID：34816013 PMCID：PMC8593789 DOI：10.1002/jgh3.12663

免费 PMC 文章
抽象的

目的：研究乐伐替尼（LEN）在肝病病因学中的治疗效果，尤其是非病毒性肝细胞癌（HCC）。

方法和结果：67 例接受 LEN 治疗的不可切除的晚期 HCC (u-HCC) 患者，包括 26 例丙型肝炎病毒 (HCV)、19 例乙型肝炎病毒 (HBV)、11 例酒精和 11 例非酒精性脂肪性肝炎 (NASH) 病例被追溯招募。使用单变量和多变量 Cox 比例风险模型来确定生存的预测因素。非病毒（酒精和 NASH）组的客观缓解率高于病毒组（59.1% [13/22] vs. 46.7% [21/45]）。非病毒组的无进展生存期显着长于病毒组（13.7 个月与 6.6 个月；风险比 [HR] 0.324；95% 置信区间 [CI] 0.174-0.602；P < 0.01）。同样，非病毒组的中位总生存期 (OS) 显着长于病毒组（不可评估 vs. 15.9 个月；HR = 0.277；95% CI = 0.116-0.662；P < 0.01）。多变量分析显示，门静脉侵犯（HR = 5.327，P = 0.0025）、治疗线（HR = 0.455，P = 0.023）和病因（HR = 0.180，P = 0.00055）是与 u-OS 相关的重要独立因素接受 LEN 治疗的 HCC 患者。

结论：我们的结果表明 LEN 对非病毒 u-HCC 比对病毒 u-HCC 更有效。

关键词：atezolizumab；贝伐单抗；乐伐替尼。

© 2021 作者。 JGH Open 由Journal of Gastroenterology and Hepatology Foundation 和John Wiley & Sons Australia, Ltd. 出版。

StephenW

Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
Tetsu Tomonari  1 , Yasushi Sato  2 , Hironori Tanaka  1 , Takeshi Mitsuhashi  1 , Akihiro Hirao  1 , Takahiro Tanaka  1 , Tatsuya Taniguchi  1 , Koichi Okamoto  1 , Masahiro Sogabe  1 , Hiroshi Miyamoto  1 , Naoki Muguruma  1 , Tetsuji Takayama  1
Affiliations
Affiliations

    1
    Department of Gastroenterology and Oncology, Institute of Biomedical Sciences Tokushima University Graduate School Tokushima Japan.
    2
    Department of Community Medicine for Gastroenterology and Oncology Tokushima University Graduate School of Biomedical Sciences Tokushima Japan.

    PMID: 34816013 PMCID: PMC8593789 DOI: 10.1002/jgh3.12663

Free PMC article
Abstract

Aim: To investigate the therapeutic effect of lenvatinib (LEN) in liver disease etiology, especially nonviral hepatocellular carcinoma (HCC).

Methods and results: Sixty-seven patients with unresectable advanced HCC (u-HCC) treated with LEN and consisting of 26 hepatitis C virus (HCV), 19 hepatitis B virus (HBV), 11 alcohol, and 11 nonalcoholic steatohepatitis (NASH) cases were retrospectively recruited. Univariate and multivariate Cox proportional hazard models were used to determine predictive factors for survival. The objective response rate in the nonviral (alcohol and NASH) group was higher than that in the viral group (59.1% [13/22] vs. 46.7% [21/45]). Progression-free survival was significantly longer in the nonviral group than in the viral group (13.7 vs. 6.6 months; hazard ratio [HR] 0.324; 95% confidence interval [CI] 0.174-0.602; P < 0.01). Similarly, median overall survival (OS) was significantly longer in the nonviral group than in the viral group (not evaluable vs. 15.9 months; HR = 0.277; 95% CI = 0.116-0.662; P < 0.01). Multivariate analysis revealed that portal vein invasion (HR = 5.327, P = 0.0025), treatment line (HR = 0.455, P = 0.023), and etiology (HR = 0.180, P = 0.00055) were significant independent factors associated with OS in u-HCC patients treated with LEN.

Conclusion: Our results suggest that LEN is more effective against nonviral u-HCC than against viral u-HCC.

Keywords: atezolizumab; bevacizumab; lenvatinib.

© 2021 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

StephenW

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jgh3.12663